WFIRM 3D bioprinted Body on a Chip responds to billion dollar screening deficiency

On average, 90% of new drugs developed by pharmaceutical companies in the U.S. fail to make it to a commercial market due to inadequacy of the current screening process. As a result, the manufacturers and researchers involved are seeking a better alternative to up the odds of the industry's roulette, and save money in a […]

from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2kBvsIn
via IFTTT